Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q2 2021 Net Income$28.01M$28.01MN/M vs Q2 2021 EPS Diluted$5.58$5.58N/M vs Q2 2021 Operating Income-$7,562,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,070,000N/M ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end